Health Care • Biotechnology: Pharmaceutical Preparations
$22.36 ▼ -0.68
(-2.95%)
MKT CAP: $2.51B • VOL: 648.5K
52W L $16 52W H $28
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$19
MEDIAN
$25
MEAN
$25
HIGH
$30
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE ZLAB TAPE
ZLAB // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $27.06 | $25.71 | 2025-02-14 | $20.35 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $28.17 | $26.38 | 2025-02-06 | $21.02 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $25.49 | $24.60 | 2025-01-29 | $21.47 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $22.81 | — | 2025-01-17 | $21.91 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $19.68 | $21.24 | 2025-01-09 | $19.90 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $26.61 | $23.25 | 2024-12-18 | $19.45 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $21.69 | $22.58 | 2024-12-04 | $20.79 | -4.3% | 48% | C |